In an effort to blunt the high price of hepatitis C treatments, France plans to selectively tax drug makers when the total cost of their medicines exceeds a certain amount each year, according to Reuters.
The government says a “progressive contribution scheme” has been designed to ensure all patients can access new and more effective treatments, while limiting the impact on national finances, the news service writes.
Read More